Aragen Life Sciences and FAR Biotech Enter Neurodegeneration Collaboration

Aragen Life Sciences, an Indian contract research and development organization, and FAR Biotech, a US-based computational drug discovery company, announced on May 30, 2023 a collaboration to advance preclinical programs in neurodegeneration on May 30, 2023. Under the collaboration, Aragen will use its experimental discovery platform to advance FAR’s small-molecule program.

"We are encouraged by the in-silico molecules we've seen coming out of FAR Biotech over the past several months and look forward to helping them advance their neurodegeneration program,” said Simon Haydar, senior vice-president and head of Integrated Drug Discovery, Aragen, in a company press release. “We are confident that the outcome will be novel therapeutic candidates for a high-impact target that has proven hard to drug."

"A key therapeutic area for FAR Biotech is neurodegeneration, where we believe our computational approach can deliver structurally diverse, novel molecules that move us closer to overcoming Alzheimer's, Parkinson's and other related diseases that have thus far proven intractable,” said Martin Martinov, CEO, FAR Biotech, in the release. “We are very pleased to be collaborating with Aragen—who we regard as a highly complementary expert partner that can help to accelerate our neurodegeneration program."